about
Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials.Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma.HOPX hypermethylation promotes metastasis via activating SNAIL transcription in nasopharyngeal carcinoma.A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma.Impact of marital status at diagnosis on survival and its change over time between 1973 and 2012 in patients with nasopharyngeal carcinoma: a propensity score-matched analysis.Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials.Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis.Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.Prognostic value of nutritional risk screening 2002 scale in nasopharyngeal carcinoma: A large-scale cohort study.Anti-epidermal growth factor receptor therapy concurrently with induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.The current status of clinical trials focusing on nasopharyngeal carcinoma: A comprehensive analysis of ClinicalTrials.gov database.Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinomaRelationship between pretreatment concentration of plasma Epstein-Barr virus DNA and tumor burden in nasopharyngeal carcinoma: An updated interpretationIdentification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapyComparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysisSpontaneous remission of residual post-therapy plasma Epstein-Barr virus DNA and its prognostic implication in nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysisThe development and external validation of simplified T category classification for nasopharyngeal carcinoma to improve the prognostic value in the intensity-modulated radiotherapy era.Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal CarcinomaCharacteristics of Radiotherapy Trials Compared With Other Oncological Clinical Trials in the Past 10 YearsQuality of Abstracts Reporting Randomized Clinical Trials Presented at a Major Oncology ConferenceThyroid dose-volume thresholds for the risk of radiation-related hypothyroidism in nasopharyngeal carcinoma treated with intensity-modulated radiotherapy-A single-institution studyConcurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trialDevelopment and validation of an immune checkpoint-based signature to predict prognosis in nasopharyngeal carcinoma using computational pathology analysisNasopharyngeal carcinomaDeep Learning for Automated Contouring of Primary Tumor Volumes by MRI for Nasopharyngeal CarcinomaInduction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinomaEvidence Underlying Recommendations and Payments from Industry to Authors of the National Comprehensive Cancer Network Guidelines
P50
Q30980856-EE63C8C7-A843-4412-BCC5-ED8EAE884738Q32073414-0AB90F39-656B-468C-A724-6BAFE02331A9Q37630359-EF522C2E-0C68-43A2-AAE5-D9A1E3E25536Q46090271-FD0B92D0-87A5-4168-9DD5-1668DB65DCBCQ47142827-417F6465-5FCB-43EB-AE5F-6E636591B901Q50066646-BB243C78-F372-40B8-82D5-6B887AACD609Q50947118-C06043AF-632A-44DB-94E4-303B1CF7C72CQ50986703-8E11C786-7636-4F22-9CEF-0BFBF021888CQ52602498-F45658CA-A034-47E1-B930-DBD2C3175F29Q52633490-3247A58A-68CA-4A75-9362-C9DB03386DCBQ54965220-776C4D5C-E407-4515-B5FE-1E049945022AQ57796235-0C09E650-F696-4301-BE4B-BA89A56139D5Q58093740-6DE5562C-18EF-4CB6-9592-8EF3231CA4DCQ58574577-C11D5CEF-EA57-49B3-9AB4-3FCF8B5AC7C1Q58576344-B2A9BE64-97F6-4F75-B58B-3C03415AAEF3Q59349775-0574A0F5-0163-4104-8496-833A7F24D556Q64997511-AAE0B74B-61D5-448D-8C35-1D3D194A24C4Q68691403-936CD16E-1919-4AF7-87FF-991EB6C922EEQ88813122-730CABC2-5C65-4146-9D40-A41F795BC2F8Q88851366-EAFAA70B-CAE4-4F08-AEAF-E9CCDB5CAC01Q90330610-F0F8F1CE-FE39-4A37-80BF-74FBEC22D6EFQ90913239-C19B44B3-EE47-464C-B081-E79CD0899201Q91270906-7AD5010A-BD08-4E9E-9A60-C9403F3F30A4Q92614329-56F819B0-5817-49CB-8C91-E8FC2DD8140EQ92624706-BE4DECDD-23B5-49F8-90F9-CCCC26CA9D33Q93020610-D24AE64B-7DFF-469A-B977-0130F6E28F00Q93249821-83F36163-830C-4C1F-9B2F-306C6032CA20
P50
description
onderzoeker
@nl
researcher ORCID: 0000-0002-1137-9349
@en
name
Jun Ma
@ast
Jun Ma
@en
Jun Ma
@nl
Jun Ma
@sl
type
label
Jun Ma
@ast
Jun Ma
@en
Jun Ma
@nl
Jun Ma
@sl
prefLabel
Jun Ma
@ast
Jun Ma
@en
Jun Ma
@nl
Jun Ma
@sl
P106
P31
P496
0000-0002-1137-9349